The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study
<p>Abstract</p> <p>Background</p> <p>Gastrointestinal stromal tumors (GIST) mutational status is recognized factor related to the results of tyrosine kinase inhibitors therapy such as imatinib (IM) or sunitinib (SU). Arterial hypertension (AH) is common adverse event re...
Main Authors: | Rutkowski Piotr, Bylina Elżbieta, Klimczak Anna, Świtaj Tomasz, Falkowski Sławomir, Kroc Jacek, Ługowska Iwona, Brzeskwiniewicz Magdalena, Melerowicz Wojciech, Osuch Czesław, Mierzejewska Ewa, Wasielewski Kacper, Woźniak Agnieszka, Grzesiakowska Urszula, Nowecki Zbigniew I, Siedlecki Janusz A, Limon Janusz |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2012-03-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://www.biomedcentral.com/1471-2407/12/107 |
Similar Items
-
Sunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectives
by: Mulet-Margalef N, et al.
Published: (2016-12-01) -
Treatment of gastrointestinal stromal tumours in paediatric and young adult patients with sunitinib: a multicentre case series
by: Piotr Rutkowski, et al.
Published: (2017-11-01) -
Oral administration of sunitinib malate for long-term survival of a patient with multiple lung metastases from renal leiomyosarcoma
by: Li X, et al.
Published: (2016-07-01) -
The analysis of the long-term outcomes of sorafenib therapy in routine practice in imatinib and sunitinib resistant gastrointestinal stromal tumors (GIST)*
by: Piotr Rutkowski, et al.
Published: (2017-12-01) -
Inhibition of FGF2-Mediated Signaling in GIST—Promising Approach for Overcoming Resistance to Imatinib
by: Sergei Boichuk, et al.
Published: (2020-06-01)